Overview
About ADAXION Therapeutics
ADAXION Therapeutics is transforming the future of biotherapeutics by tackling one of the biggest challenges in drug development: immunogenicity.
Based in San Diego, the company is developing innovative treatments for immune-mediated and inflammatory diseases using its proprietary ADAx platform. This technology is designed to deimmunize protein therapeutics—preventing the formation of anti-drug antibodies (ADAs) that can compromise efficacy and trigger harmful immune responses.
The ADAx platform uses proprietary CD22 ligands to selectively eliminate therapeutic-specific B cells while preserving the full functionality of the biologic and maintaining overall immune competence. This drug-specific approach enables the development of first- and best-in-class biologics that would otherwise be limited by immunogenicity. With a growing pipeline and a focus on addressing unmet medical needs, ADAXION is unlocking the full potential of biologics to enhance therapeutic performance and expand their clinical impact.
Based in San Diego, the company is developing innovative treatments for immune-mediated and inflammatory diseases using its proprietary ADAx platform. This technology is designed to deimmunize protein therapeutics—preventing the formation of anti-drug antibodies (ADAs) that can compromise efficacy and trigger harmful immune responses.
The ADAx platform uses proprietary CD22 ligands to selectively eliminate therapeutic-specific B cells while preserving the full functionality of the biologic and maintaining overall immune competence. This drug-specific approach enables the development of first- and best-in-class biologics that would otherwise be limited by immunogenicity. With a growing pipeline and a focus on addressing unmet medical needs, ADAXION is unlocking the full potential of biologics to enhance therapeutic performance and expand their clinical impact.